Utah Medical Products (NASDAQ:UTMD) was upgraded by investment analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a report issued on Friday.
Utah Medical Products (NASDAQ:UTMD) opened at $95.20 on Friday. Utah Medical Products has a fifty-two week low of $58.50 and a fifty-two week high of $98.00. The company has a market cap of $353.27, a PE ratio of 41.57 and a beta of 0.77.
Utah Medical Products (NASDAQ:UTMD) last announced its earnings results on Tuesday, January 30th. The medical instruments supplier reported $0.95 EPS for the quarter. Utah Medical Products had a net margin of 20.54% and a return on equity of 18.85%. The company had revenue of $10.20 million during the quarter.
In related news, CEO Kevin L. Cornwell sold 1,095 shares of the firm’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $91.01, for a total transaction of $99,655.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Ernst G. Hoyer sold 1,529 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $88.08, for a total transaction of $134,674.32. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 16,169 shares of company stock valued at $1,466,903. 8.80% of the stock is currently owned by corporate insiders.
Several hedge funds have recently bought and sold shares of UTMD. Acadian Asset Management LLC acquired a new stake in shares of Utah Medical Products during the fourth quarter worth approximately $130,000. MetLife Investment Advisors LLC acquired a new stake in shares of Utah Medical Products during the fourth quarter worth approximately $163,000. SG Americas Securities LLC acquired a new stake in shares of Utah Medical Products during the fourth quarter worth approximately $189,000. The Manufacturers Life Insurance Company boosted its holdings in shares of Utah Medical Products by 15.4% during the second quarter. The Manufacturers Life Insurance Company now owns 3,355 shares of the medical instruments supplier’s stock worth $242,000 after purchasing an additional 448 shares during the period. Finally, Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Utah Medical Products during the fourth quarter worth approximately $289,000. Institutional investors and hedge funds own 67.12% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://ledgergazette.com/2018/03/23/utah-medical-products-utmd-stock-rating-upgraded-by-bidaskclub.html.
About Utah Medical Products
Utah Medical Products, Inc (UTMD) is engaged in the business of producing medical devices that are disposable and for hospital use. The Company’s product categories include labor and delivery/obstetrics, including fetal monitoring accessories, Vacuum-Assisted Delivery Systems (VAD), and other labor and delivery tools; neonatal intensive care, including DISPOSA-HOOD, DELTRAN PLUS and GESCO; gynecology/urology/electrosurgery, including LETZ System, FINESSE+ Generator, EPITOME, PATHFINDER PLUS, HOLMIUM LASER FIBRES, LIBERTY System, ENDOCURETTE, TVUS/HSG-Cath and LUMIN, and blood pressure monitoring, including DELTRAN Disposable Pressure Transducer (DPT), and pressure monitoring accessories, components and other molded parts.
Receive News & Ratings for Utah Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Utah Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.